Loomis Sayles & Co. L P Grows Position in Jazz Pharmaceuticals plc (NASDAQ:JAZZ)

Loomis Sayles & Co. L P boosted its stake in shares of Jazz Pharmaceuticals plc (NASDAQ:JAZZ) by 59.0% in the 4th quarter, according to its most recent disclosure with the SEC. The institutional investor owned 169,621 shares of the specialty pharmaceutical company’s stock after acquiring an additional 62,969 shares during the period. Loomis Sayles & Co. L P owned 0.28% of Jazz Pharmaceuticals worth $20,889,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently bought and sold shares of JAZZ. NEOS Investment Management LLC purchased a new position in shares of Jazz Pharmaceuticals during the fourth quarter valued at about $206,000. Sava Infond d.o.o. bought a new position in Jazz Pharmaceuticals during the fourth quarter valued at approximately $421,000. JPMorgan Chase & Co. boosted its stake in Jazz Pharmaceuticals by 4.8% during the fourth quarter. JPMorgan Chase & Co. now owns 1,587,541 shares of the specialty pharmaceutical company’s stock valued at $195,506,000 after buying an additional 72,007 shares during the last quarter. Mitsubishi UFJ Trust & Banking Corp grew its holdings in Jazz Pharmaceuticals by 20.2% during the 4th quarter. Mitsubishi UFJ Trust & Banking Corp now owns 47,325 shares of the specialty pharmaceutical company’s stock valued at $5,828,000 after buying an additional 7,963 shares in the last quarter. Finally, CoreFirst Bank & Trust bought a new stake in Jazz Pharmaceuticals in the 4th quarter worth approximately $28,000. 89.14% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

A number of research firms have recently commented on JAZZ. UBS Group upgraded Jazz Pharmaceuticals from a “neutral” rating to a “buy” rating and increased their target price for the company from $145.00 to $179.00 in a research report on Friday, March 7th. JPMorgan Chase & Co. lifted their price objective on shares of Jazz Pharmaceuticals from $200.00 to $209.00 and gave the stock an “overweight” rating in a research note on Wednesday, February 26th. Royal Bank of Canada reduced their target price on shares of Jazz Pharmaceuticals from $179.00 to $178.00 and set an “outperform” rating on the stock in a report on Wednesday, February 26th. Cantor Fitzgerald downgraded shares of Jazz Pharmaceuticals from an “overweight” rating to a “neutral” rating and increased their price target for the company from $140.00 to $150.00 in a report on Wednesday, February 26th. Finally, HC Wainwright lifted their price target on Jazz Pharmaceuticals from $200.00 to $217.00 and gave the stock a “buy” rating in a research report on Monday, March 10th. One equities research analyst has rated the stock with a hold rating, thirteen have given a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, Jazz Pharmaceuticals currently has a consensus rating of “Buy” and an average price target of $187.71.

Jazz Pharmaceuticals Stock Performance

Shares of Jazz Pharmaceuticals stock opened at $122.92 on Friday. The company has a quick ratio of 3.74, a current ratio of 4.26 and a debt-to-equity ratio of 1.46. The stock’s fifty day moving average is $132.30 and its two-hundred day moving average is $122.43. Jazz Pharmaceuticals plc has a 52 week low of $99.06 and a 52 week high of $148.06. The company has a market capitalization of $7.47 billion, a PE ratio of 17.31, a price-to-earnings-growth ratio of 1.04 and a beta of 0.44.

Insider Activity

In other Jazz Pharmaceuticals news, CEO Bruce C. Cozadd sold 1,500 shares of the business’s stock in a transaction dated Thursday, January 2nd. The shares were sold at an average price of $123.43, for a total value of $185,145.00. Following the completion of the sale, the chief executive officer now directly owns 425,525 shares of the company’s stock, valued at $52,522,550.75. The trade was a 0.35 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CMO Robert Iannone sold 7,080 shares of the firm’s stock in a transaction that occurred on Friday, March 7th. The stock was sold at an average price of $138.60, for a total transaction of $981,288.00. Following the transaction, the chief marketing officer now directly owns 82,024 shares in the company, valued at approximately $11,368,526.40. This trade represents a 7.95 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 28,736 shares of company stock valued at $4,022,825. 4.20% of the stock is currently owned by company insiders.

Jazz Pharmaceuticals Profile

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.